Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhaoke OphthalmologyFRA:9FX +0.78%47 Debt-to-Equity is 0.19 as of Dec. 2025, which is 217% above its 10-year median of 0.06. GuruFocus rates FRA:9FX with a GF Score™ of 47/100 and a GF Value™ of €0.27. The stock has 5 warning signs investors should review. Among 963 Biotechnology companies, Zhaoke Ophthalmology ranks worse than 52.75% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zhaoke Ophthalmology's Debt-to-Equity or its related term are showing as below:
FRA:9FX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.21 Med: 0.06 Max: 0.19
Current: 0.19
During the past 7 years, the highest Debt-to-Equity Ratio of Zhaoke Ophthalmology was 0.19. The lowest was -1.21. And the median was 0.06.
FRA:9FX's Debt-to-Equity is ranked worse than 52.75% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:9FX: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zhaoke Ophthalmology Debt-to-Equity Related Terms
Zhaoke Ophthalmology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9FX vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (FRA:9FX) has a Debt-to-Equity of 0.19 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zhaoke Ophthalmology and its competitors. This is 217% above median its historical median of 0.06. According to the industry distribution chart, Zhaoke Ophthalmology ranks #508 out of 963 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Zhaoke Ophthalmology's Debt-to-Equity too high?
Zhaoke Ophthalmology's current Debt-to-Equity of 0.19 is 217% above median its 10-year median of 0.06. The Biotechnology industry median Debt-to-Equity is 0.16. Zhaoke Ophthalmology's value of 0.19 is 18.8% above this industry median. Based on the distribution chart, Zhaoke Ophthalmology ranks #508 out of 963 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #508 out of 963 companies for Debt-to-Equity. This places Zhaoke Ophthalmology in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Zhaoke Ophthalmology's value of 0.19 is 18.8% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.16, Zhaoke Ophthalmology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhaoke Ophthalmology's current Debt-to-Equity of 0.19 is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zhaoke Ophthalmology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current Debt-to-Equity is 0.19, which is 217% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current Debt-to-Equity of 0.19. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current Debt-to-Equity is 0.19, which is 217% above median its 10-year median of 0.06 and 18.8% above the Biotechnology industry median of 0.16. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current Debt-to-Equity is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.
Key valuation signals for FRA:9FX:
Debt-to-Equity: 0.19 (217% above median its 10-year median of 0.06)
GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
Industry Position: 18.8% above the Biotechnology median (#508 of 963)
No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for FRA:9FX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9FX has been successfully added to your 
